Introduction: Neutrophilic dermatoses (NDs) often occur secondary to inflammatory conditions, medication exposure, and hematologic malignancy. While malignancy-associated NDs (MA-NDs) have been well reported among those with hematologic cancers, little is known about drug-induced NDs (DI-NDs) within this population. The objective of this study was to compare the presentations and outcomes of patients with hematologic malignancies who developed MA-NDs and DI-NDs. Methods: Cases of ND occurring between 2013 and 2023 among those with hematologic malignancies were identified from the electronic medical records of our institution. Patient characteristics, recent medication exposures, cancer mutations, and disease outcomes were reviewed. Patients were categorized with DI-ND if they were recently exposed to one of four medications known to be commonly associated with ND or were otherwise categorized with MA-ND. We report a descriptive analysis of cases of DI-ND and MA-ND. Results: We identified 52 patients with ND and co-occurring hematologic malignancy including 16 cases of DI-ND (30.8%) and 36 cases of MA-ND (69.2%). The most common ND in both groups was Sweet’s syndrome. Chronic underlying conditions including solid tumors, inflammatory disorders, chronic viral infection, and tobacco use were more common among those with MA-ND. Among those with DI-ND, tyrosine kinase inhibitors were the most commonly associated drugs (43.8%). The most common cancer mutation among those with DI-ND was FLT3 (43.8%), while the most common mutation among those with MA-ND was TP-53 (19.4%). Among those who had died at the time of data collection, 90.0% of those with DI-ND and 66.7% of those with MA-ND died within 1 year of ND diagnosis. Conclusion: Most cases of ND occurring with hematologic malignancies develop secondary to cancer rather than drug exposure. Different cancer mutations may predispose to DI-ND and MA-ND. Further research is needed to establish diagnostic criteria for DI-ND and to determine the pathogenic role of specific cancer mutations, particularly FLT3, in the development of ND.

1.
Heath
MS
,
Ortega-Loayza
AG
.
Insights into the pathogenesis of Sweet’s syndrome
.
Front Immunol
.
2019
;
10
:
414
.
2.
Walker
DC
,
Cohen
PR
.
Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced sweet’s syndrome
.
J Am Acad Dermatol
.
1996
;
34
(
5 Pt 2
):
918
23
.
3.
Nelson
CA
,
Noe
MH
,
McMahon
CM
,
Gowda
A
,
Wu
B
,
Ashchyan
HJ
, et al
.
Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center
.
J Am Acad Dermatol
.
2018
;
78
(
2
):
303
9.e4
.
4.
Kazmi
SM
,
Pemmaraju
N
,
Patel
KP
,
Cohen
PR
,
Daver
N
,
Tran
KM
, et al
.
Characteristics of Sweet Syndrome in patients with acute myeloid leukemia
.
Clin Lymphoma Myeloma Leuk
.
2015
;
15
(
6
):
358
63
.
5.
Gille
J
,
Spieth
K
,
Kaufmann
R
.
Sweet’s syndrome as initial presentation of diffuse large B-cell lymphoma
.
J Am Acad Dermatol
.
2002
;
46
(
2 Suppl Case Reports
):
S11
3
.
6.
Woodrow
SL
,
Munn
SE
,
Basarab
T
,
Russell Jones
R
.
Sweet’s syndrome in association with non-Hodgkin’s lymphoma
.
Clin Exp Dermatol
.
1996
;
21
(
5
):
357
9
.
7.
Mahood
JM
,
Sneddon
IB
.
Pyoderma gangrenosum complicating non‐Hodgkin’s lymphoma
.
Br J Dermatol
.
1980
;
102
(
2
):
223
5
.
8.
Varadarajan
N
,
Boni
A
,
Elder
DE
,
Bagg
A
,
Micheletti
R
,
Perl
AE
, et al
.
FLT3 inhibitor-associated neutrophilic dermatoses
.
JAMA Dermatol
.
2016
;
152
(
4
):
480
2
.
9.
Yang
L
,
Zhang
R
,
Ma
H
.
Sweet syndrome induced by FLT3 inhibitors: case report and literature review
.
Hematology
.
2024
;
29
(
1
):
2337230
.
10.
Kennedy
VE
,
Smith
CC
.
FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies
.
Front Oncol
.
2020
;
10
:
612880
.
11.
Qin
G
,
Han
X
.
The prognostic value of TP53 mutations in adult acute myeloid leukemia: a meta-analysis
.
Transfus Med Hemother
.
2023
;
50
(
3
):
234
44
.
12.
Sharma
R
,
Johnson
RH
,
Heidari
A
,
Malerich
M
,
Stull
WR
,
Cobos
E
.
Neutrophilic dermatosis in myelodysplastic syndrome and chronic active hepatitis C
.
J Investig Med High Impact Case Rep
.
2021
;
9
:
23247096211037458
.
13.
Pourmorteza
M
,
Tawadros
F
,
Bader
G
,
Al-Tarawneh
M
,
Cook
E
,
Shams
W
, et al
.
Successful treatment of pyoderma gangrenosum with cryoglobulinemia and hepatitis C
.
Am J Case Rep
.
2016
;
17
:
434
8
.
14.
Croitoru
D
,
Sibbald
C
,
Alavi
A
,
Brooks
S
,
Piguet
V
.
Challenging the association of hepatitis C and pyoderma gangrenosum
.
Br J Dermatol
.
2021
;
185
(
5
):
1047
8
.
15.
Philips
CA
,
Paramaguru
R
,
Augustine
P
.
Strange case of dimorphic skin rash in a patient with cirrhosis: atypical herpes simplex and Sweet’s syndrome
.
BMJ Case Rep
.
2017
;
2017
:
bcr2017220743
.
16.
Cunha
DG
,
Campos-do-Carmo
G
,
Marujo
JM
,
Verardino
GC
.
Paraneoplastic Sweet’s syndrome
.
Bras Dermatol
.
2018
;
93
(
4
):
576
8
.
17.
Shakshouk
H
,
deCampos-Stairiker
M
,
Kody
S
,
Stenzel
P
,
Xia
E
,
Mostaghimi
A
, et al
.
Mortality and autopsy findings in patients with pyoderma gangrenosum: a multi-institutional series
.
Dermatology
.
2024
;
240
(
2
):
352
6
.
You do not currently have access to this content.